CIGB-428

CIGB-428 is a biopharmaceutical candidate developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB) specifically for the treatment of diabetic neuropathy. It is a formulation of recombinant human epidermal growth factor (rhEGF). The therapeutic approach leverages the neurotrophic and regenerative properties of EGF, which binds to the epidermal growth factor receptor (EGFR) expressed on various cell types, including neurons and glial cells. By activating EGFR-mediated signaling pathways, CIGB-428 aims to promote nerve repair, enhance cell survival, and improve nerve conduction velocity, thereby addressing the underlying peripheral nerve damage associated with chronic diabetes.

Brand names

Regen-D 150Regen-D150Regen-D-150Regen D 150 Gel

Other names

recombinant human epidermal growth factorrhEGF